Biological Markers to Identify Early Sepsis and Acute Lung Injury

Chimei Medical Center

Status: Completed

Conditions: Acute Lung Injury; Sepsis

Study type: Observational

Funder types: Other

Identifiers

NCT00825357

CM-IRB09509002

Details and patient eligibility

About

There are no clear markers to identify sepsis and acute lung injury at early stage in clinical settings which would result in improved survival of the patients. In collaboration with the research team led by Dr. Zhang at St. Michael's Hospital, Toronto, we have initiated a pilot study looking for biological markers to detect severe sepsis and ARDS. We have found that human neutrophils peptides (a-defensins), certain coagulation variables and cytokine levels are very sensitive markers to differentiate severe sepsis, ARDS from cardiovascular diseases in ICU patients. These findings may provide valuable information for therapeutic guideline in clinical practice. The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury. We will examine the roles of three components of markers including inflammation, neutrophil activation and coagulation. We are hoping that this proposed translational research will help develop novel therapeutic strategy in sepsis and acute lung injury patients.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Meet diagnostic criteria of ≧2 SIRS or acute lung injury.
• Get agreement of patient's attending physician and inform consent form patient or family.

Exclusion criteria

• Use Antibiotics over 24 hrs（only SIRS group）.
• Active bleeding.
• Pregnancy.
• Active Cancer (refer to malignancy which is recently diagnosed, under treatment, or relapsed)
• VS or Subject or Family refuse